Rigel Pharmaceuticals Inc. (New)
Symbol: RIGL (NASDAQ)
29.66
▲ (0.92%) 0.270
Company Description:
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Key Stats
- Today's Open: $29.71
- Today's High: $30.502
- Today's Low: $29.075
- Today's Volume: 297.48K
- Yesterday Close: $29.39
- Yesterday High: $31.92
- Yesterday Low: $29.23
- Yesterday Volume: 447.59K
- Last Min Volume: 0
- Last Min High: $29.714
- Last Min Low: $29.66
- Last Min VWAP: $0
Company Profile
- Name: Rigel Pharmaceuticals Inc. (New)
- Website: https://www.rigel.com
- Listed Date: 2000-11-29
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001034842
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $537.58M
- Round Lot: 100
- Outstanding Shares: 17.94M
- Asset Type: CS
RECENT FILINGS FOR RIGL
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-07 | SCHEDULE 13G/A | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-06 | S-8 | View |
| 2025-08-05 | SCHEDULE 13G/A | View |
| 2025-08-05 | 10-Q | View |
| 2025-08-05 | 8-K | View |
| 2025-05-28 | 4 | View |
| 2025-05-28 | 4 | View |
| 2025-05-28 | 4 | View |
| 2025-05-28 | 4 | View |
| 2025-05-28 | 4 | View |
| 2025-05-28 | 4 | View |
| 2025-05-23 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-06 | 8-K | View |
Latest News on RIGL